Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Exploring HER2 as a Pan Tumor Biomarker

January 11th 2024

Martin Dietrich, MD, PhD, presents a thorough analysis of HER2 as a pan-tumor biomarker, underscoring its universal importance in the field of oncology.

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Allegheny Health Network Oncology Experts Dive Into Updates Within the Gynecologic Oncology Space

January 10th 2024

Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the 2023 ESMO Congress.

Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer

January 10th 2024

Bradley Monk, MD, shares the promising potential of anti-HER2 therapy in cervical cancer and discusses encouraging results from recent trials, emphasizing the importance of testing for HER2 and considering anti-HER2 antibody drug conjugates as a treatment option.

Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer

January 10th 2024

Experts in gynecologic oncology discuss the positive results of TV-301, a confirmatory trial for TV-204, raising the possibility of moving tisotumab vedotin earlier in the treatment of patients with cervical cancer, and the potential to combine it with pembrolizumab.

FDA Grants Priority Review to Tisotumab Vedotin sBLA for Recurrent or Metastatic Cervical Cancer

January 9th 2024

The FDA has granted priority review to a sBLA seeking to convert the accelerated approval of tisotumab vedotin to full approval in select patients with cervical cancer.

2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer

January 9th 2024

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

January 8th 2024

Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).

Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

January 3rd 2024

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs

January 3rd 2024

Experts detail the management of ocular toxicity associated with tisotumab vedotin in patients with cervical cancer, emphasizing the need for eye care professionals and a team approach, along with addressing peripheral neuropathy.

Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

January 3rd 2024

Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.

Markman Shares Hopes for 2024, Underscoring Need for Meaningful Decision Support Across Oncology

December 28th 2023

Maurie Markman, MD, discusses current challenges faced with developing robust decision support tools for oncologists and projects additional research efforts dedicated to finding a way to leverage CAR T-cell therapies in solid tumors to improve patient outcomes.

Markman Reflects on Key Advances Made in 2023 in the Realm of Gynecologic Cancers and Beyond

December 27th 2023

Maurie Markman, MD, highlights inroads made with immunotherapy, antibody-dependent cytotoxic agents, and molecular testing across oncology.

Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

December 27th 2023

Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.

Staging and Biomarker Testing For Patients With Cervical Cancer

December 27th 2023

David M. O’Malley, MD, discusses cervical cancer epidemiology, risk factors, and diagnosis, highlighting the importance of HPV vaccinations, regular PAP smears, and the use of various biomarkers for treatment decision making.

Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

December 26th 2023

Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.

Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

December 26th 2023

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Being Part of the Contagious Enthusiasm

December 24th 2023

In a full-circle scenario, Cedars-Sinai Cancer, based in Los Angeles, California, welcomed back Margaret Liang, MD, MSHPM, in July 2023 to the institution where she completed her fellowship.

Gynecologic Oncologists Highlight Ongoing Areas of Exploration Throughout the Treatment Armamentarium

December 22nd 2023

Michael P. Stany, MD, discusses the optimization of PARP inhibitors in the upfront maintenance setting of ovarian cancer, the benefit of novel targets and immunotherapy combinations, and the role of immunotherapy in the treatment of advanced endometrial cancer.